Seek Returns logo

LLY vs. MS: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at LLY and MS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolLLYMS
Company NameEli Lilly and CompanyMorgan Stanley
CountryUnited StatesUnited States
GICS SectorHealth CareFinancials
GICS IndustryPharmaceuticalsCapital Markets
Market Capitalization739.95 billion USD255.59 billion USD
ExchangeNYSENYSE
Listing DateJune 1, 1972February 23, 1993
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of LLY and MS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

LLY vs. MS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolLLYMS
5-Day Price Return2.85%-1.30%
13-Week Price Return-2.12%11.21%
26-Week Price Return-7.71%31.84%
52-Week Price Return-13.08%50.51%
Month-to-Date Return4.15%-1.30%
Year-to-Date Return-1.17%24.79%
10-Day Avg. Volume4.02M6.01M
3-Month Avg. Volume4.14M5.26M
3-Month Volatility41.96%17.67%
Beta0.411.24

Profitability

Return on Equity (TTM)

LLY

88.36%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

MS

13.95%

Capital Markets Industry

Max
38.97%
Q3
22.24%
Median
13.52%
Q1
8.61%
Min
-4.25%

MS’s Return on Equity of 13.95% is on par with the norm for the Capital Markets industry, indicating its profitability relative to shareholder equity is typical for the sector.

LLY vs. MS: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Net Profit Margin (TTM)

LLY

25.91%

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

MS

13.06%

Capital Markets Industry

Max
69.91%
Q3
37.24%
Median
24.30%
Q1
13.06%
Min
-15.18%

MS’s Net Profit Margin of 13.06% is aligned with the median group of its peers in the Capital Markets industry. This indicates its ability to convert revenue into profit is typical for the sector.

LLY vs. MS: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Operating Profit Margin (TTM)

LLY

32.37%

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

MS

17.07%

Capital Markets Industry

Max
84.86%
Q3
47.16%
Median
32.23%
Q1
18.65%
Min
-21.87%

MS’s Operating Profit Margin of 17.07% is in the lower quartile for the Capital Markets industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

LLY vs. MS: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Profitability at a Glance

SymbolLLYMS
Return on Equity (TTM)88.36%13.95%
Return on Assets (TTM)16.02%1.15%
Net Profit Margin (TTM)25.91%13.06%
Operating Profit Margin (TTM)32.37%17.07%
Gross Profit Margin (TTM)82.64%54.42%

Financial Strength

Current Ratio (MRQ)

LLY

1.28

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

MS

0.29

Capital Markets Industry

Max
3.37
Q3
1.81
Median
1.01
Q1
0.56
Min
0.04

For the Capital Markets industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

LLY vs. MS: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Debt-to-Equity Ratio (MRQ)

LLY

2.18

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

With a Debt-to-Equity Ratio of 2.18, LLY operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

MS

7.68

Capital Markets Industry

Max
6.52
Q3
2.79
Median
0.96
Q1
0.28
Min
0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Capital Markets industry.

LLY vs. MS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Interest Coverage Ratio (TTM)

LLY

20.36

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

MS

1.25

Capital Markets Industry

Max
107.59
Q3
48.41
Median
10.85
Q1
4.56
Min
-36.26

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Capital Markets industry.

LLY vs. MS: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Financial Strength at a Glance

SymbolLLYMS
Current Ratio (MRQ)1.280.29
Quick Ratio (MRQ)0.530.29
Debt-to-Equity Ratio (MRQ)2.187.68
Interest Coverage Ratio (TTM)20.361.25

Growth

Revenue Growth

LLY vs. MS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

LLY vs. MS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

LLY

0.68%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

LLY’s Dividend Yield of 0.68% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

MS

2.53%

Capital Markets Industry

Max
9.02%
Q3
4.54%
Median
2.55%
Q1
1.27%
Min
0.00%

MS’s Dividend Yield of 2.53% is consistent with its peers in the Capital Markets industry, providing a dividend return that is standard for its sector.

LLY vs. MS: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Dividend Payout Ratio (TTM)

LLY

36.46%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

MS

43.20%

Capital Markets Industry

Max
199.38%
Q3
99.28%
Median
60.67%
Q1
32.00%
Min
0.00%

MS’s Dividend Payout Ratio of 43.20% is within the typical range for the Capital Markets industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

LLY vs. MS: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Dividend at a Glance

SymbolLLYMS
Dividend Yield (TTM)0.68%2.53%
Dividend Payout Ratio (TTM)36.46%43.20%

Valuation

Price-to-Earnings Ratio (TTM)

LLY

53.86

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

At 53.86, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

MS

17.10

Capital Markets Industry

Max
51.69
Q3
29.42
Median
17.58
Q1
12.55
Min
5.59

MS’s P/E Ratio of 17.10 is within the middle range for the Capital Markets industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

LLY vs. MS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Price-to-Sales Ratio (TTM)

LLY

13.96

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

With a P/S Ratio of 13.96, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

MS

2.23

Capital Markets Industry

Max
14.65
Q3
7.29
Median
4.53
Q1
2.26
Min
0.04

In the lower quartile for the Capital Markets industry, MS’s P/S Ratio of 2.23 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

LLY vs. MS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Price-to-Book Ratio (MRQ)

LLY

40.43

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

MS

2.08

Capital Markets Industry

Max
10.83
Q3
5.12
Median
2.66
Q1
1.19
Min
0.37

MS’s P/B Ratio of 2.08 is within the conventional range for the Capital Markets industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

LLY vs. MS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Capital Markets industry benchmarks.

Valuation at a Glance

SymbolLLYMS
Price-to-Earnings Ratio (TTM)53.8617.10
Price-to-Sales Ratio (TTM)13.962.23
Price-to-Book Ratio (MRQ)40.432.08
Price-to-Free Cash Flow Ratio (TTM)369.8711.47